Cited 0 times in 
Cited 3 times in 
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Passaro, A. | - |
| dc.contributor.author | Wang, J. | - |
| dc.contributor.author | Shah, S. | - |
| dc.contributor.author | Bauml, J. M. | - |
| dc.contributor.author | Campelo, R. G. | - |
| dc.contributor.author | Cho, B. C. | - |
| dc.date.accessioned | 2024-10-04T02:43:26Z | - |
| dc.date.available | 2024-10-04T02:43:26Z | - |
| dc.date.created | 2025-02-27 | - |
| dc.date.issued | 2024-03 | - |
| dc.identifier.issn | 0923-7534 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/200572 | - |
| dc.description.abstract | [No abstract available] | - |
| dc.description.statementOfResponsibility | restriction | - |
| dc.language | English | - |
| dc.publisher | Oxford University Press | - |
| dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
| dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
| dc.rights | CC BY-NC-ND 2.0 KR | - |
| dc.title | Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study | - |
| dc.type | Article | - |
| dc.contributor.college | College of Medicine (의과대학) | - |
| dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
| dc.contributor.googleauthor | Passaro, A. | - |
| dc.contributor.googleauthor | Wang, J. | - |
| dc.contributor.googleauthor | Shah, S. | - |
| dc.contributor.googleauthor | Bauml, J. M. | - |
| dc.contributor.googleauthor | Campelo, R. G. | - |
| dc.contributor.googleauthor | Cho, B. C. | - |
| dc.identifier.doi | 10.1016/j.annonc.2023.11.012 | - |
| dc.relation.journalcode | J00171 | - |
| dc.identifier.eissn | 1569-8041 | - |
| dc.identifier.pmid | 38029840 | - |
| dc.contributor.alternativeName | Cho, Byoung Chul | - |
| dc.contributor.affiliatedAuthor | Cho, B. C. | - |
| dc.identifier.scopusid | 2-s2.0-85182646798 | - |
| dc.identifier.wosid | 001198054800001 | - |
| dc.citation.volume | 35 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 328 | - |
| dc.citation.endPage | 329 | - |
| dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.35(3) : 328-329, 2024-03 | - |
| dc.identifier.rimsid | 85168 | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.description.journalClass | 1 | - |
| dc.subject.keywordPlus | VENOUS THROMBOEMBOLISM | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.type.docType | Letter | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.relation.journalResearchArea | Oncology | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.